吉西他滨联合铂类在印度晚期胆囊癌患者中的应用。

Use of gemcitabine-platinum in Indian patients with advanced gall bladder cancer.

作者信息

Sirohi Bhawna, Rastogi Sameer, Singh Ashish, Sheth Vipul, Dawood Shaheenah, Talole Sanjay, Ramadwar Mukta, Kulkarni Suyash, Shrikhande Shailesh V

机构信息

Department of Medical Oncology, Tata Memorial Centre, Parel, Mumbai, India.

出版信息

Future Oncol. 2015;11(8):1191-200. doi: 10.2217/fon.14.295.

DOI:10.2217/fon.14.295

PMID:25832876

Abstract

BACKGROUND

Gemcitabine-platinum (Gem-P) is the current standard for patients with advanced gall bladder cancer.

MATERIALS & METHODS: This is retrospective analysis of a prospectively maintained database of 210 patients with advanced gall bladder cancer treated with Gem-P between January 2012 and September 2013.

RESULTS

Median age was 53 years, 65.2% females. In total,158 patients had metastatic and 52 had locoregional disease. Median number of cycles was 5 (1-12). At a median follow-up of 10 months, median overall survival/progression-free survival was 10/5 months, respectively. On multivariate analysis, patients who underwent prior surgery for primary and locoregional disease had a significantly better progression-free survival and those with locoregional disease had a significantly better overall survival. A total of 45.7% received second-line chemotherapy.

CONCLUSION

Use of Gem-P in Indian patients leads to slightly worse outcomes suggesting an aggressive biology.

摘要

背景

吉西他滨联合铂类（Gem-P）是晚期胆囊癌患者目前的标准治疗方案。

材料与方法

这是一项对2012年1月至2013年9月期间接受Gem-P治疗的210例晚期胆囊癌患者的前瞻性维护数据库进行的回顾性分析。

结果

中位年龄为53岁，女性占65.2%。共有158例患者发生转移，52例有局部区域疾病。中位周期数为5（1 - 12）。中位随访10个月时，中位总生存期/无进展生存期分别为10/5个月。多因素分析显示，曾因原发性和局部区域疾病接受过手术的患者无进展生存期显著更好，而有局部区域疾病的患者总生存期显著更好。共有45.7%的患者接受了二线化疗。